Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

April 13, 2017 updated by: Raymond Yeung, University of Washington

A Phase II Study Of Adjuvant Intravenous Irinotecan Following Resection With Or Without Radiofrequency Ablation (RFA), Of Hepatic Metastases From Colorectal Carcinoma

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug after surgery and radiofrequency ablation may kill any remaining tumor cells.

PURPOSE: Phase II trial to determine the effectiveness of surgery with or without radiofrequency ablation followed by irinotecan in treating patients who have colorectal cancer that is metastatic to the liver.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Determine the disease-free survival in patients with hepatic metastases from primary colorectal carcinoma treated with surgical resection with or without radiofrequency ablation followed by irinotecan.
  • Determine the overall survival in patients treated with this regimen.
  • Determine the treatment-related toxicity of this regimen in these patients.
  • Correlate the measurement of molecular markers with clinical outcome in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to treatment with radiofrequency ablation in addition to resection (yes vs no).

Patients undergo surgical resection with or without radiofrequency ablation. Beginning 4-8 weeks after surgery, patients receive irinotecan IV over 90 minutes on day 1. Chemotherapy repeats every 3 weeks for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Hospital
  • United States
    • Ohio
      • Cleveland, Ohio, United States, 44106-5065
        • Ireland Cancer Center
    • Washington
      • Seattle, Washington, United States, 98195
        • University of Washington School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 120 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed primary colorectal adenocarcinoma

  • Hepatic metastases that are considered completely resectable

    • No more than 4 metastases by dual phase CT scan OR

  • Hepatic metastases that are not completely resectable but are amenable to complete destruction with resection and radiofrequency ablation

    • More than 4 metastases allowed if all disease can be resected or destroyed in situ with radiofrequency ablation
  • No extrahepatic disease in any location
  • No recurrent or second primary colorectal cancer by colonoscopy within the past year
  • Received prior adjuvant chemotherapy with a fluorouracil-based regimen with the last dose at least 1 month prior to surgery
  • No prior radiofrequency ablation with residual viable intrahepatic disease by CT scan
  • No plans to be treated with radiofrequency ablation alone without surgical resection

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 5 times ULN
  • No Gilbert's disease or other known defect in hepatic conjugation or glucuronidation

Renal:

  • Creatinine no greater than 1.5 times ULN

Cardiovascular:

  • No myocardial infarction within the past 6 months
  • No congestive heart failure requiring therapy

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for 30 days after study
  • No other malignancy within the past 5 years except inactive non-melanoma skin cancer or carcinoma in situ of the cervix
  • No active serious infection
  • No other serious underlying medical condition or severe concurrent disease that would preclude study participation
  • No dementia, significantly altered mental status, or psychiatric illness that would preclude study participation
  • No known hypersensitivity to irinotecan
  • No known infection with HIV or AIDS
  • No uncontrolled diabetes mellitus
  • No history of seizures
  • No drug or alcohol abuse within the past year

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • No prior irinotecan

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy to more than 30% of bone marrow
  • No prior radiotherapy to the liver
  • At least 3 months since prior radiotherapy to the pelvis or other areas

Surgery:

  • See Disease Characteristics
  • No prior resection of hepatic metastases (wedge biopsy allowed)

Other:

  • No concurrent phenytoin, phenobarbital, or other antiepileptic medication
  • No concurrent enrollment in other investigational drug trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Washington

Collaborators

National Cancer Institute (NCI)

Investigators

  • Study Chair: Kevin G. Billingsley, MD, University of Washington

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2001

Primary Completion (Actual)

October 1, 2004

Study Completion (Actual)

October 1, 2005

Study Registration Dates

First Submitted

February 14, 2002

First Submitted That Met QC Criteria

January 26, 2003

First Posted (Estimate)

January 27, 2003

Study Record Updates

Last Update Posted (Actual)

April 17, 2017

Last Update Submitted That Met QC Criteria

April 13, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 18033
  • UWASH-1200
  • CWRU-040106
  • UWASH-440E-ONC-0020-250
  • NCI-G01-2045
  • CWRU-UWMC-1200

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe